MaxCyte (MXCT) News Today → It's time to ween off Chinese lithium! (From Smallcaps Daily) (Ad) Free MXCT Stock Alerts $4.96 +0.10 (+2.06%) (As of 04:15 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 10 at 4:53 PM | marketbeat.comCadian Capital Management LP Makes New Investment in MaxCyte, Inc. (NASDAQ:MXCT)Cadian Capital Management LP bought a new position in shares of MaxCyte, Inc. (NASDAQ:MXCT - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 5,644,898 shares of the company's stock, vJune 6, 2024 | marketbeat.comMaxCyte, Inc. (NASDAQ:MXCT) Stock Holdings Lifted by Mudita Advisors LLPMudita Advisors LLP grew its holdings in MaxCyte, Inc. (NASDAQ:MXCT - Free Report) by 35.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,881,349 shares of the company's stock after purchasinJune 6, 2024 | marketbeat.comMaxCyte (NASDAQ:MXCT) Shares Gap Up to $4.59MaxCyte (NASDAQ:MXCT) Shares Gap Up to $4.59May 29, 2024 | globenewswire.comMaxCyte to Participate in William Blair 44th Annual Growth Stock ConferenceMay 22, 2024 | globenewswire.comMaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and DevelopmentMay 19, 2024 | marketbeat.comMassachusetts Financial Services Co. MA Boosts Position in MaxCyte, Inc. (NASDAQ:MXCT)Massachusetts Financial Services Co. MA lifted its position in MaxCyte, Inc. (NASDAQ:MXCT - Free Report) by 29.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,537,114 shares ofMay 12, 2024 | marketbeat.comRoubaix Capital LLC Invests $1.82 Million in MaxCyte, Inc. (NASDAQ:MXCT)Roubaix Capital LLC purchased a new position in shares of MaxCyte, Inc. (NASDAQ:MXCT - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 386,201 shares of the company's stock, valued at approximately $1,815,000. RMay 10, 2024 | marketbeat.comMaxCyte, Inc. Forecasted to Post Q1 2025 Earnings of ($0.14) Per Share (NASDAQ:MXCT)MaxCyte, Inc. (NASDAQ:MXCT - Free Report) - Stock analysts at William Blair issued their Q1 2025 earnings per share estimates for shares of MaxCyte in a research report issued to clients and investors on Wednesday, May 8th. William Blair analyst M. Larew anticipates that the company will earn ($0May 8, 2024 | marketbeat.comMaxCyte (NASDAQ:MXCT) Sees Large Volume IncreaseMaxCyte (NASDAQ:MXCT) Sees Unusually-High Trading VolumeMay 8, 2024 | lse.co.ukMaxCyte shares rise amid double-digit revenue increaseMay 8, 2024 | finance.yahoo.comMaxCyte Inc (MXCT) Q1 2024 Earnings Call Transcript Highlights: Robust Revenue Growth and ...May 7, 2024 | investorplace.comMXCT Stock Earnings: MaxCyte Beats EPS, Beats Revenue for Q1 2024May 7, 2024 | globenewswire.comMaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 GuidanceMay 7, 2024 | globenewswire.comMaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 GuidanceMay 3, 2024 | morningstar.comMaxCyte Inc MYE0April 26, 2024 | finance.yahoo.comMaxCyte, Inc. (MXCT)April 23, 2024 | marketbeat.comMaxCyte (NASDAQ:MXCT) Receives Overweight Rating from StephensStephens restated an "overweight" rating and set a $11.00 price objective on shares of MaxCyte in a research report on Tuesday.April 10, 2024 | globenewswire.comMaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024April 5, 2024 | msn.comMesa Laboratories maintains quarterly dividend of $0.16April 2, 2024 | globenewswire.comMaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)March 29, 2024 | insidertrades.comInsider Selling: MaxCyte, Inc. (NASDAQ:MXCT) Director Sells 5,000 Shares of StockMarch 28, 2024 | marketbeat.comJohn Joseph Johnston Sells 5,000 Shares of MaxCyte, Inc. (NASDAQ:MXCT) StockMaxCyte, Inc. (NASDAQ:MXCT - Get Free Report) Director John Joseph Johnston sold 5,000 shares of the firm's stock in a transaction dated Tuesday, March 26th. The stock was sold at an average price of $4.41, for a total value of $22,050.00. Following the transaction, the director now directly owns 120,583 shares in the company, valued at approximately $531,771.03. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.March 20, 2024 | marketbeat.comWillis Investment Counsel Invests $2.59 Million in MaxCyte, Inc. (NASDAQ:MXCT)Willis Investment Counsel purchased a new position in MaxCyte, Inc. (NASDAQ:MXCT - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 550,000 shares of the company's stock, valued at approximately $March 17, 2024 | finance.yahoo.comDowngrade: Here's How Analysts See MaxCyte, Inc. (LON:MXCT) Performing In The Near TermMarch 15, 2024 | finanznachrichten.deMaxCyte, Inc: MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 GuidanceMarch 14, 2024 | finance.yahoo.comMaxCyte, Inc. (LON:MXCT) Just Reported And Analysts Have Been Cutting Their EstimatesMarch 13, 2024 | marketbeat.comMaxCyte (NASDAQ:MXCT) Receives Outperform Rating from William BlairWilliam Blair reissued an "outperform" rating on shares of MaxCyte in a research report on Wednesday.March 13, 2024 | marketwatch.comMaxCyte Shares Rise 13% After 4Q Beat, Reaffirmed GuidanceMarch 12, 2024 | globenewswire.comMaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 GuidanceMarch 12, 2024 | globenewswire.comMaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 GuidanceMarch 6, 2024 | finanznachrichten.deMaxCyte, Inc.: MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary ResultsMarch 5, 2024 | marketbeat.comWilliam Blair Reiterates "Outperform" Rating for MaxCyte (NASDAQ:MXCT)William Blair reissued an "outperform" rating on shares of MaxCyte in a report on Tuesday.March 4, 2024 | globenewswire.comMaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary ResultsMarch 4, 2024 | globenewswire.comMaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary ResultsFebruary 19, 2024 | marketbeat.comBlair William & Co. IL Boosts Stock Position in MaxCyte, Inc. (NASDAQ:MXCT)Blair William & Co. IL increased its holdings in shares of MaxCyte, Inc. (NASDAQ:MXCT - Free Report) by 94.4% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 251,851 shares of the company's stock afteFebruary 16, 2024 | marketbeat.comMaven Securities LTD Buys New Position in MaxCyte, Inc. (NASDAQ:MXCT)Maven Securities LTD bought a new stake in MaxCyte, Inc. (NASDAQ:MXCT - Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 204,175 shares of the company's stock, valued at approximately $637,000.February 9, 2024 | finance.yahoo.comMaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor ConferencesJanuary 30, 2024 | finance.yahoo.comMaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen’s Investigational Allogeneic, Off-the-Shelf Cell Therapies for CancersJanuary 23, 2024 | markets.businessinsider.comMaxCyte Signs SPL Agreement With ImugeneJanuary 9, 2024 | msn.comWhy Cell Engineering Company MaxCyte Shares Are Up TodayJanuary 9, 2024 | seekingalpha.comCOMM, NKTX and AVIR are among after hour moversJanuary 5, 2024 | benzinga.comMaxCyte Stock (NASDAQ:MXCT) Dividends: History, Yield and DatesJanuary 3, 2024 | finance.yahoo.comMaxCyte and Lion TCR form Partnership to Support Global Expansion of Lion TCR's TCR-T Cell PipelineJanuary 2, 2024 | marketbeat.comMaxCyte, Inc. (NASDAQ:MXCT) Sees Significant Growth in Short InterestMaxCyte, Inc. (NASDAQ:MXCT - Get Free Report) saw a large increase in short interest in the month of December. As of December 15th, there was short interest totalling 4,000,000 shares, an increase of 29.9% from the November 30th total of 3,080,000 shares. Approximately 4.4% of the company's stock are sold short. Based on an average trading volume of 1,050,000 shares, the short-interest ratio is currently 3.8 days.January 2, 2024 | finanznachrichten.deMaxCyte, Inc: MaxCyte Confirms Appointment of Maher Masoud as President, Chief Executive Officer and DirectorJanuary 2, 2024 | msn.comMaxCyte gets new CEO and PresidentJanuary 2, 2024 | finance.yahoo.comMaxCyte Confirms Appointment of Maher Masoud as President, Chief Executive Officer and DirectorDecember 28, 2023 | marketbeat.comMaxCyte, Inc. (NASDAQ:MXCT) Director John Joseph Johnston Sells 5,000 SharesMaxCyte, Inc. (NASDAQ:MXCT - Get Free Report) Director John Joseph Johnston sold 5,000 shares of the business's stock in a transaction dated Tuesday, December 26th. The shares were sold at an average price of $4.53, for a total value of $22,650.00. Following the sale, the director now owns 120,583 shares in the company, valued at approximately $546,240.99. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.December 15, 2023 | finance.yahoo.comWith 74% institutional ownership, MaxCyte, Inc. (LON:MXCT) is a favorite amongst the big gunsDecember 14, 2023 | marketbeat.comFY2023 EPS Estimates for MaxCyte, Inc. (NASDAQ:MXCT) Raised by AnalystMaxCyte, Inc. (NASDAQ:MXCT - Free Report) - Equities research analysts at William Blair increased their FY2023 EPS estimates for MaxCyte in a research note issued to investors on Tuesday, December 12th. William Blair analyst M. Larew now anticipates that the company will post earnings per share o Get MaxCyte News Delivered to You Automatically Sign up to receive the latest news and ratings for MXCT and its competitors with MarketBeat's FREE daily newsletter. Email Address Biden Nomination CANCELED? (Ad)And I believe when they do take the oath of office, their fingers will be crossed… and America will descend into chaos. Click here now to see my urgent election warning. MXCT Media Mentions By Week MXCT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MXCT News Sentiment▼1.300.76▲Average Medical News Sentiment MXCT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MXCT Articles This Week▼21▲MXCT Articles Average Week Get MaxCyte News Delivered to You Automatically Sign up to receive the latest news and ratings for MXCT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Heron Therapeutics News AnaptysBio News National Research News OmniAb News Absci News MeiraGTx News MacroGenics News Arcturus Therapeutics News Harvard Bioscience News Luna Innovations News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MXCT) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...Smallcaps Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredMoonshot Coins for the Current Crypto RunDid you see bitcoin crossed $70k again? Don't miss the next bull run. Because while Bitcoin and Ethereum s...Crypto 101 Media | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredThe Most Dangerous Time for 401k OwnersThe world's most powerful CEO just issued a grave warning to Americans... "This may be the most dangerous t...Birch Gold | Sponsored